NCT03039322已完成不适用
Golgi Protein 73 for Diagnosis of HCC in Egyptian Patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 90
- 主要终点
- Golgi protein correlated with presence of HCC
研究概览
简要总结
This case-control study was conducted on 90 patients who were equally divided into two groups. Group 1 included 45 patients with HCV-related chronic liver disease without clinical or radiological evidence of HCC (control group), and Group 2 included 45 patients diagnosed to have HCC by Triphasic abdominal CT (patient group). Serum AFP and GP73 were measured using ELISA technique
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients were older than 18 years.
排除标准
- •patients with hepatic focal lesions not due to HCC such as Hemangioma, Hepatic cyst, and liver metastases; patients infected with HIV; patients with any autoimmune disease; or patients with metastatic disease.
结局指标
主要结局
Golgi protein correlated with presence of HCC
时间窗: within one year
次要结局
未报告次要终点
研究者
Shereen Abou Bakr Saleh
Assisstant Professor
Ain Shams University
相似试验
Unknown
不适用
A Clinical Study of GP73 as a Hepatocellular Carcinoma (HCC) Tumor MarkHepatocellular CarcinomaNCT00902902Peking Union Medical College Hospital
已完成
1 期
Transarterial Chemoembolization (TACE) Therapy of Hepatocellular Carcinoma (HCC) With Blocking Tumor Blood Temporarily and Enhancing PerfusionHepatocellular CarcinomaNCT00826384Eastern Hepatobiliary Surgery Hospital352
已完成
不适用
Research on Surgery and Micro-Invasive Treatment in Recurrent Primary Liver CancerHepatocellular CarcinomaNCT00822562Eastern Hepatobiliary Surgery Hospital100
已完成
不适用
Comparing Diagnostic Accuracy for Liver Tumours Between the Combination of CEUS and CEMRI Versus CECT and CEMRIHepatocellular Carcinoma (HCC)NCT03267290National Taiwan University Hospital12
Unknown
2 期
Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic CholangiocarcinomaBile Duct CancerIntrahepatic CholangiocarcinomaNCT03086993Delcath Systems Inc.295